Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Lispro Mix 25 vs Glargine in Type 2 Diabetes
NCT00551356Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2002
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin lispro mix25 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change from baseline to endpoint in 2h postprandial blood glucose excursion after breakfast at 16 weeks. Started Nov 2002; status: completed.
02
Drugs
insulin lispro mix25
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00551356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00551356.